Shares of Sweetgreen plunged another 7.1% to $5.83 on August 17, extending a brutal sell-off that has erased roughly half the stock's value since the company slashed its outlook on August 6. The fast-casual salad chain isn't linked to any cyclospora outbreak, yet consumer anxiety about fresh greens is dragging traffic — and investor confidence — through the floor. Sweetgreen's Salad Days Are Over — But Is a $700 Million Valuation Already Pricing In the Worst?
Shares slid another 7.1% to $5.83 on August 17, extending a punishing decline that has shaved roughly 40% off Sweetgreen's market value since the company posted second-quarter results on August 6. The salad chain isn't responsible for the cyclospora outbreak ravaging consumer confidence in fresh produce, but it's paying the price anyway — and the question now is whether the stock has fallen far enough to reflect the damage.
A Food Scare It Didn't Cause Is Costing Millions Anyway
The cyclospora outbreak, though not linked to Sweetgreen's supply chain, is estimated to impact full-year EBITDA (a measure of operating cash flow) by $7 million to $10 million due to consumer sentiment shifts.
Nearly 23,000 confirmed and probable cyclospora cases have been reported in 47 states since May.
Investigators traced the outbreak to shredded iceberg lettuce served at Taco Bell — a product Sweetgreen doesn't even use. But when headlines warn consumers against salads and leafy greens, a brand built entirely on raw produce becomes collateral damage.
The Guidance Cut Tells a Grim Traffic Story
Full-year guidance was slashed, with comparable sales now expected to decline 7% to 8% and adjusted EBITDA projected at a loss of $23 million to $27 million. That compares with Sweetgreen's prior forecast of just a 2%–4% same-store sales dip. Management expects the outbreak to drag third-quarter comparable sales by an additional 600 to 700 basis points — meaning traffic could remain deeply depressed into the fall. The company already posted a $26.3 million net loss and essentially break-even EBITDA in Q2.
There Were Green Shoots Before the Outbreak Hit
Same-store sales fell 6.2% in Q2, partly from deliberate promotions, but transaction trends had improved from down 11.2% in Q1 to roughly flat in June before health headlines derailed momentum.
Wraps hit 20% sales incidence and drove a five-point frequency increase. The turnaround plan was gaining traction — which is precisely why the timing stings.
Analysts Are Cutting Targets, Not Running for the Exits
Bank of America trimmed its price target to $6.40, DA Davidson to $5.50, and Oppenheimer to $8.50 — all within striking distance of today's price. With a market cap near $748 million, 119 million shares outstanding, and $142.6 million in cash , Sweetgreen isn't facing a liquidity crisis. But with recovery timing uncertain, investors are being asked to trust a turnaround inside a health scare whose duration no one can forecast.